Skip to content

Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage

Anatomical Clinical Correlations. Neuropsychological and Brain Medical Imaging Study in Brain Damaged Subjects.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01849549
Acronym
CORAC
Enrollment
346
Registered
2013-05-08
Start date
2013-05-01
Completion date
2022-03-01
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Lesions, Cerebrovascular Disorders, Degenerative Diseases, Developmental Pathology

Keywords

neuropsychological Study, brain Imaging

Brief summary

Two groups of subjects will be constitute: (i) patients with circumscribed brain injury (including stroke, vascular malformations, tumor or circumscribed infectious lesions) or degenerative disorders and selective cognitive disorders; (ii) healthy control subjects. The objective of this project is to evaluate specific neuropsychological deficits and apply current brain imaging techniques (anatomical, diffusion, functional) to patients suffering from these cognitive deficits due to brain damage, in order to elucidate the brain mechanisms underlying these deficits.

Interventions

BEHAVIORALNeuropsychological testing

Experimental test about cognitive deficit of interest and standard neuropsychological tests.

OTHERMRI

Anatomical, diffusion, and/or functional MRI

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 18 and 80 years * french language * effective contraception for women during the study * informed consent * no alcohol intake the day before the exam * for patients only, focal cerebral lesion (stroke, malformation, tumor, inflammatory, infectious, traumatic), neonatal pathology or degenerative disease with cognitive deficit

Exclusion criteria

* for healthy volunteers: previous neurological history (except non complicated migraine), previous psychiatric history (except depression with good evolution or anxiety with maximum one anxiolytic treatment), or severe cranial traumatism * for patients: vigilance disorders, severe depression or anxiety. * for both: psychotropic medication other than a hypnotic or an anxiolytic at low doses without dose modification for at least one month, severe visual or auditory impairment, patient without judicial or administrative liberty, measure of legal protection or no capable to express their consent, pregnancy or breastfeeding, contraindication for MRI, participation in another trial or former involvement in another trial within one month

Design outcomes

Primary

MeasureTime frameDescription
Cognitive deficit3 to 6 monthsThe cognitive deficit of interest will depend on the localization of the brain lesion. The outcome measure could be a standardized neuropsychological test or an experimental test specifically elaborated for this protocol.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORDavid Wallon, Doctor

Neurology Department

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026